Rochester, NY 6/13/2009 1:10:43 AM
Afternoon Stocks In Play - presented by WhisperFromWallStreet.com - TPI,OPK,ENA
Tianyin Pharmaceutical Co. - Opko Health, Inc. - Enova Systems, Inc.
Afternoon Stocks In Play - presented by WhisperFromWallStreet.com - TPI,OPK,ENA
WhisperfromWallStreet.com is an award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, and teaching you how to become a better trader. We can now even deliver this information instantly to our "Penny Stock Alert" gadget that sits right on your Microsoft Vista or iGoogle desktop. You will know from the instant you get your confirmation email that we are different. What do you have to lose except a little time and a chance to really learn how to make money trading.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
TIANYIN PHARMACEUTCL,TPI
Tianyin Pharmaceutical Co., Inc., through its subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd., engages in the development, manufacture, marketing, and sale of traditional Chinese medicines and other pharmaceuticals in the People's Republic of China. It manufactures a portfolio of 34 products, as well as has a pipeline of 51 products, which are pending regulatory approvals with the China State Food and Drug Administration. The company was founded in 1994 and is based in Chengdu, the People's Republic of China.
Last Trade: 3.10
Day's Range: 2.83 - 3.17
52wk Range: 0.68 - 2.84
Volume: 136,992
---
OPKO HEALTH INC.,OPK
Opko Health, Inc., a specialty healthcare company, engages in the discovery, development, and commercialization of proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of ophthalmic disorders. The company's product candidates include Bevasiranib, which is in Phase I/II clinical trial for the treatment of diabetic retinopathy (DR)/diabetic macular edema (DME); Civamide that is in Phase I/II clinical trial for the treatment of dry eye; Budesonide, a Phase II clinical trial product, which targets inflammatory and allergic conditions of the eye; and Doxovir, a Phase II clinical trial product for the treatment of viral conjunctivitis and other viral infections.
Last Trade: 1.63
Day's Range: 1.46 - 1.66
52wk Range: N/A
Volume: 95,708
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
--
ENOVA SYSTEMS INC,ENA
Enova Systems, Inc. engages in the development and production of digital power management systems for transportation vehicles and stationary power generation systems in the United States, Asia, and Europe. The company also develops and produces software, firmware, and hardware for applications in alternative power markets. It focuses on digital power conversion, power management, and system integration. The company offers power management systems, which control and monitor electric power in an automotive or commercial application, such as an automobile or a stand-alone power generator; drive systems comprising an electric motor, an electronics control unit, and a gear unit that offers power to electric vehicles; hybrid systems that eliminates external recharging of the battery system; hydrogen fuel cell based system; and stationary power systems utilize similar components to those, which are in a mobile drive system in addition to other elements.
Last Trade: 1.10
Day's Range: 1.05 - 1.22
52wk Range: 0.12 - 4.70
Volume: 45,246
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
